Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma : A network metanalysis of phase III trials
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Dual programmed cell death-1 and vascular endothelial growth factor pathway inhibition is the novel standard of care for patients with unresectable hepatocellular carcinoma. Direct comparisons between first-line treatments are lacking.
METHOD: We conducted a literature search in MEDLINE (https://pubmed.ncbi.nlm.nih.gov), the Cochrane library (https://www.cochranelibrary.com) and Embase (www.embase.com) between January 2007 and February 2022. We included phase III randomised controlled trials that tested immune-checkpoint inhibitors or tyrosine kinase inhibitors, including sorafenib, lenvatinib and donafenib, and evaluated as primary end-point overall survival (OS) or progression-free survival (PFS). Studies testing loco-regional therapies were excluded. The primary end-point was to compare the efficacy of first-line options in terms of OS and PFS. We extracted Hazard ratios (HR) and 95% confidence intervals (95% CI) for OS and PFS and performed a frequentist network meta-analysis with fixed effect multivariable meta-regression models. The research protocol was registered in PROSPERO, an international prospective register of systematic reviews (registration code CRD42022312489).
FINDINGS: Literature review yielded 13709 results, after duplicates removal and exclusion of not relevant studies, 70 papers were available for screening. After full-text review, 9 studies were eligible for analysis. Atezolizumab plus bevacizumab reduced the risk of death compared to placebo (HR 0·40; 95% CI 0·28-0·57), sorafenib (HR 0·58; 95% CI 0·42-0·80), lenvatinib (HR 0·63; 95% CI 0·44-0·89), atezolizumab plus cabozantinib (HR 0·64; 95% CI 0·43-0·97), nivolumab (HR 0·68; 95% CI 0·48-0·98) and donafenib (HR 0·69; 95% CI 0·48-0·99). Atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab (HR 0·74; 95% CI 0·52-1·06) and sintilimab plus IBI305 (HR 1·02; 95% CI 0·67-1·55) in reducing the risk of death. Efficacy was associated with a higher risk of grade 3 adverse events.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
---|---|
Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 174(2022) vom: 01. Okt., Seite 57-67 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Fulgenzi, Claudia A M [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.09.2022 Date Revised 08.11.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejca.2022.06.058 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM344887464 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM344887464 | ||
003 | DE-627 | ||
005 | 20231226023812.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejca.2022.06.058 |2 doi | |
028 | 5 | 2 | |a pubmed24n1149.xml |
035 | |a (DE-627)NLM344887464 | ||
035 | |a (NLM)35970037 | ||
035 | |a (PII)S0959-8049(22)00410-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Fulgenzi, Claudia A M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma |b A network metanalysis of phase III trials |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.09.2022 | ||
500 | |a Date Revised 08.11.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a BACKGROUND: Dual programmed cell death-1 and vascular endothelial growth factor pathway inhibition is the novel standard of care for patients with unresectable hepatocellular carcinoma. Direct comparisons between first-line treatments are lacking | ||
520 | |a METHOD: We conducted a literature search in MEDLINE (https://pubmed.ncbi.nlm.nih.gov), the Cochrane library (https://www.cochranelibrary.com) and Embase (www.embase.com) between January 2007 and February 2022. We included phase III randomised controlled trials that tested immune-checkpoint inhibitors or tyrosine kinase inhibitors, including sorafenib, lenvatinib and donafenib, and evaluated as primary end-point overall survival (OS) or progression-free survival (PFS). Studies testing loco-regional therapies were excluded. The primary end-point was to compare the efficacy of first-line options in terms of OS and PFS. We extracted Hazard ratios (HR) and 95% confidence intervals (95% CI) for OS and PFS and performed a frequentist network meta-analysis with fixed effect multivariable meta-regression models. The research protocol was registered in PROSPERO, an international prospective register of systematic reviews (registration code CRD42022312489) | ||
520 | |a FINDINGS: Literature review yielded 13709 results, after duplicates removal and exclusion of not relevant studies, 70 papers were available for screening. After full-text review, 9 studies were eligible for analysis. Atezolizumab plus bevacizumab reduced the risk of death compared to placebo (HR 0·40; 95% CI 0·28-0·57), sorafenib (HR 0·58; 95% CI 0·42-0·80), lenvatinib (HR 0·63; 95% CI 0·44-0·89), atezolizumab plus cabozantinib (HR 0·64; 95% CI 0·43-0·97), nivolumab (HR 0·68; 95% CI 0·48-0·98) and donafenib (HR 0·69; 95% CI 0·48-0·99). Atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab (HR 0·74; 95% CI 0·52-1·06) and sintilimab plus IBI305 (HR 1·02; 95% CI 0·67-1·55) in reducing the risk of death. Efficacy was associated with a higher risk of grade 3 adverse events | ||
650 | 4 | |a Comparative Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CTLA-4 | |
650 | 4 | |a Clinical trials | |
650 | 4 | |a Hepatocellular cancer | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a PD-1 | |
650 | 4 | |a Survival | |
650 | 4 | |a VEGF | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
650 | 7 | |a Phenylurea Compounds |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Quinolines |2 NLM | |
650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
650 | 7 | |a Bevacizumab |2 NLM | |
650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
650 | 7 | |a Nivolumab |2 NLM | |
650 | 7 | |a 31YO63LBSN |2 NLM | |
650 | 7 | |a Sorafenib |2 NLM | |
650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
650 | 7 | |a lenvatinib |2 NLM | |
650 | 7 | |a EE083865G2 |2 NLM | |
700 | 1 | |a D'Alessio, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Airoldi, Chiara |e verfasserin |4 aut | |
700 | 1 | |a Scotti, Lorenza |e verfasserin |4 aut | |
700 | 1 | |a Demirtas, Coskun O |e verfasserin |4 aut | |
700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 174(2022) vom: 01. Okt., Seite 57-67 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
773 | 1 | 8 | |g volume:174 |g year:2022 |g day:01 |g month:10 |g pages:57-67 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2022.06.058 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 174 |j 2022 |b 01 |c 10 |h 57-67 |